A new analysis has shown that Novartis’ crizanlizumab reduced the number of patients with sickle cell disease experiencing a pain crisis. More: Novartis crizanlizumab shows promise in sickle cell anaemia Source: News
read moreShares in German biopharma Affimed dropped near 30% after the company said it was placing a key Phase I programme of its experimental cancer immunotherapy on hold because of serious side effects observed in trials, including a patient death. More:
read moreShares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment for congenital adrenal hyperplasia (CAH) failed to meet its primary objective. More: Diurnal shares plummet on trial failure Source:
read moreFor the first time in more than 30 years children and young adults in England and Wales with the rare brain disorder XLH will have access to a new treatment option via the NHS. More: XLH patients to get routine
read moreDo you have a passion for medical information? Could you be among the first in the field to win at the hotly anticipated PharmaTimes Medical & Scientific Excellence Awards? More: The PharmaTimes Medical & Scientific Excellence Awards – could it
read moreSome new CEOs fill out their executive team roster over time as leaders from the previous regime make their exits. Not Pfizer’s. On Tuesday, the New York company unveiled the list of executives that will support incoming chief Albert Bourla
read more© 1994 - 2026 B.M. Pharmaceuticals